BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND FANCC, ENSG00000158169, 2176, RP11-80I15_2, FAC, FA3, FACC, FLJ14675 AND Treatment
12905 results:

  • 1. Assessment of secular trends of three major gynecologic cancers burden and attributable risk factors from 1990 to 2019: an age period cohort analysis.
    Liu Y; Shi W; Mubarik S; Wang F
    BMC Public Health; 2024 May; 24(1):1349. PubMed ID: 38764017
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Current data and future perspectives on DNA methylation in ovarian cancer (Review).
    Fu M; Deng F; Chen J; Fu L; Lei J; Xu T; Chen Y; Zhou J; Gao Q; Ding H
    Int J Oncol; 2024 Jun; 64(6):. PubMed ID: 38757340
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant ovarian cancer: Findings From Cohort A of the OPAL Phase II Trial.
    Liu JF; Gaillard S; Wahner Hendrickson AE; Yeku O; Diver E; Gunderson Jackson C; Arend R; Ratner E; Samnotra V; Gupta D; Chung J; Zhang H; Compton N; Baines A; Bacqué E; Liu X; Felicetti B; Konecny GE
    JCO Precis Oncol; 2024 May; 8():e2300693. PubMed ID: 38754056
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Feasibility and cost-effectiveness of genetic counselling for all patients with newly diagnosed ovarian cancer: a single-centre retrospective study.
    Schlootz S; Saner FAM; Rabaglio M; Imboden S; Wampfler J
    Swiss Med Wkly; 2024 Apr; 154():3386. PubMed ID: 38754016
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Perioperative management of a patient with unexpectedly detected early-stage ovarian mucinous carcinoma combined with progressive bulbar paralysis: a case report and literature review.
    Zhang D; Xu R; Huo T; Liu Y; Hao Z; Sun Y; Xi X; Du X; Wang L; Du J
    BMC Womens Health; 2024 May; 24(1):274. PubMed ID: 38704534
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
    Belotte J; Felicetti B; Baines AJ; YoussefAgha A; Rojas-Espaillat L; Ortiz AG; Provencher D; Vázquez RM; Cortijo LG; Zeng X
    Trials; 2024 May; 25(1):301. PubMed ID: 38702828
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. OTUB2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibition.
    Nan Y; Wu X; Luo Q; Chang W; Zhao P; Zhang L; Liu Z
    Proc Natl Acad Sci U S A; 2024 May; 121(19):e2315348121. PubMed ID: 38701117
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Tailoring postoperative management through sentinel lymph node biopsy in low- and intermediate-risk endometrial cancer - the SENTRY clinical trial.
    Sorokin P; Novozhilov M; Utkin D; Abduragimova Z; Dudina I; Nikiforchin A; Kulikova S
    Klin Onkol; 2024; 38(2):126-133. PubMed ID: 38697821
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
    Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
    Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. High-Grade Serous ovarian cancer during Pregnancy: From Diagnosis to treatment.
    Vivod G; Merlo S; Kovacevic N
    Curr Oncol; 2024 Apr; 31(4):1920-1935. PubMed ID: 38668047
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Cardiovascular mortality risk in patients with ovarian cancer: a population-based study.
    Hu ZL; Yuan YX; Xia MY; Li Y; Yang Y; Wang SN; Meng XZ; Sun MY; Wang N
    J Ovarian Res; 2024 Apr; 17(1):88. PubMed ID: 38664732
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Granulosa cell tumor of the ovary: a series of 6 cases.
    da Costa REAR; Silva MCA; Cavalcante ECX; Branco ROC; Dos Reis CA; Vieira SC
    Pan Afr Med J; 2024; 47():58. PubMed ID: 38646138
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
    Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Small bite fascial closure technique reduces incisional hernia rates in gynecologic oncology patients.
    Straubhar AM; Stroup C; Manorot A; McCool K; Rolston A; Reynolds RK; McLean K; de Bear O; Siedel J; Uppal S
    Int J Gynecol Cancer; 2024 May; 34(5):745-750. PubMed ID: 38642924
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Germline mutations in BRCA1 and BRCA2 among Brazilian women with ovarian cancer treated in the Public Health System.
    de Oliveira Ferreira C; Carneiro VCG; Araujo Mariz C
    BMC Cancer; 2024 Apr; 24(1):499. PubMed ID: 38641594
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Polycystic ovary syndrome.
    Stener-Victorin E; Teede H; Norman RJ; Legro R; Goodarzi MO; Dokras A; Laven J; Hoeger K; Piltonen TT
    Nat Rev Dis Primers; 2024 Apr; 10(1):27. PubMed ID: 38637590
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Effect of different treatment modalities on ovarian cancer patients with liver metastases: A retrospective cohort study based on SEER.
    Li N; Jin S; Wu J; Ji H; Du C; Liu B
    PLoS One; 2024; 19(4):e0299504. PubMed ID: 38635517
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Integration of single-cell RNA-seq and bulk RNA-seq data to construct and validate a cancer-associated fibroblast-related prognostic signature for patients with ovarian cancer.
    Shen L; Li A; Cui J; Liu H; Zhang S
    J Ovarian Res; 2024 Apr; 17(1):82. PubMed ID: 38627854
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.
    Tran TM; Chand Thakuri BK; Nurmukhambetova S; Lee JJ; Hu P; Tran NQ; Steimle B; Dash P; Schneider D
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609317
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Construction and analysis of competitive endogenous RNA networks and prognostic models associated with ovarian cancer based on the exoRBase database.
    Chen Z; Wang C; Ding J; Yu T; Li N; Ye C
    PLoS One; 2024; 19(4):e0291149. PubMed ID: 38603733
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 646.